Central Nervous System & Neurological Diseases

Lead text placeholder. Lorem ipsum dolor sit amet, consectetur adipisicing elit.

Articles

2019. Griego JC et al. – A Conceptual model of Angelman Syndrome and review of relevant clinical outcomes assessments (COAs)
2019. Landfeldt E et al. – A mini review and implementation model for using ataluren to treat nonsense mutation Duchenne muscular dystrophy
2019. Landfeldt E et al. – Health-related quality of life in patients with adult-onset myotonic dystrophy Type 1: A systematic review
2019. Lochmüller H et al. – The Position of Neuromuscular Patients in Shared Decision Making. Report from the 235th ENMC Workshop: Milan, Italy, January 19-20, 2018
2018. Landfeldt E et al. – Duchenne muscular dystrophy and caregiver burden: A systematic review
2018. Landfeldt E et al. – The long-term impact of multiple sclerosis on the risk of divorce
2018. Mundayat R et al. – Positive effectiveness of tafamidis in delaying disease progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 years: An analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
2018. Landfeldt E et al. – Personal income before and after diagnosis of multiple sclerosis
2018. Landfeldt E et al. – The long-term impact of early treatment of multiple sclerosis on the risk of disability pension
2017. Landfeldt E et al. Patient preferences for treatments of neuromuscular diseases: A systematic literature review
2017. Kobelt G et al. – The burden of multiple sclerosis 2015: Methods of data collection, assessment and analysis of costs, quality of life and symptoms
2017. Berger T et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Austria
2017. Dubois B et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Belgium
2017. Havrdova E et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results of the Czech Republic
2017. Rasmussen PV et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Denmark
2017. Lebrun-Frenay C et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for France
2017. Flachenecker P et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany
2017. Péntek M et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Hungary
2017. Battaglia M et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy
2017. Uitdehaag B et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for the Netherlands
2017. Selmaj K et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Poland
2017. Sá MJ et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Portugal
2017. Boyko A et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Russia
2017. Oreja-Guevara C et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Spain
2017. Brundin L et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Sweden
2017. Calabrese P et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for Switzerland
2017. Thompson A et al. – New insights into the burden and costs of multiple sclerosis in Europe: Results for the United Kingdom
2017. Wang YG et al. – Assessing narcolepsy with cataplexy in children and adolescents: Development of a cataplexy diary and the ESS-CHAD
2017. Huisman E et al. – Systematic literature review and network meta-analysis in highly active relapsing-remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
2017. Benmedjahed K et al. – Assessing sleepiness and cataplexy in children and adolescents with narcolepsy: A review of current patient-reported outcomes
2017. Kobelt G et al. – New insights into the burden and costs of multiple sclerosis in Europe
2016. Landfeldt E et al. – Sick leave and disability pension before and after diagnosis of multiple sclerosis
2016. Åkerborg Ö et al. – Cost of dementia and its correlation with dependence
2016. Landfeldt E. – Consanguinity and autosomal recessive neuromuscular disorders
2016. Chevalier J et al. – Cost-effectiveness of treatments for relapsing remitting multiple sclerosis: A French societal perspective
2015. Takizawa C et al. – Epidemiological and economic burden of Alzheimer’s disease: A systematic literature review of data across Europe and the United States of America
2014. Duracinsky M et al. – ARIZONA study: Is the risk of post-herpetic neuralgia and its burden increased in the most elderly patients?
2013. van Seventer R et al. – Validation of the Dutch version of the DN4 diagnostic questionnaire for neuropathic pain
2012. Rofail D et al. – Factors contributing to the success of folic acid public health campaigns
2012. Ghosh S et al. – Epidemiology of HIV-related neuropathy: A systematic literature review
2011. Yi Y et al. – Economic burden of neural tube defects and impact of prevention with folic acid: A literature review
2011. Chaléat-Valayer E et al. – A French observational study of botulinum toxin use in the management of children with cerebral palsy: BOTULOSCOPE
2009. Abetz L et al. – Alzheimer’s disease treatment: Assessing caregiver preferences for mode of treatment delivery
2008. Viala-Danten M et al. – Evaluation of the reliability and validity of the Medical Outcomes Study sleep scale in patients with painful diabetic peripheral neuropathy during an international clinical trial
2008. Crawford B et al. – Conceptual adequacy of the neuropathic pain symptom inventory in six countries
2003. Acquadro C et al. – Quality of life in multiple sclerosis: Translation in French Canadian of the MSQoL-54

Posters & Presentations

2017. ISPOR European Congress – Adherence issues in multiple sclerosis treatment: How can acceptance measurement help understanding patients’ concerns and working on solutions?
2017. ISPOR European Congress – PRO labeling for products approved by the European Medicines Agency (EMA) for narcolepsy
2017. Clinical Trials on Alzheimer’s Disease Meeting – Providing culturally sensitive training and monitoring to clinicians administering functional assessments in dementia global trials
2017. ACTRIMS-ECTRIMS Meeting – Effectiveness of dimethyl fumarate on disease activity and patient- reported outcomes in French subjects with relapsing-remitting multiple sclerosis in the realworld: A subgroup analysis of PROTEC
2017. ISOQOL Annual Conference – Are clinical outcome assessment (COA) data important in the evaluation of medicines for the treatment of Alzheimer’s disease approved by the FDA and the EMA?
2017. ISCTM Autumn Meeting – How to translate cognitive outcomes measures. The case study of the Parkinson’s Disease-Cognitive Rating Scale in 15 languages
2017. EAN Congress – Translating the Rapid Eye Movement (REM) Sleep Behavior Disorder Screening Questionnaire (RBDSQ) into 21 Languages using a standardized methodology
2017. EAN Congress – Translating the Parkinson´s Disease Sleep Scale (PDSS-2) into 31 Languages using a standardized methodology
2017. EAN Congress – The role of clinical outcome assessment (COA) data in the drug approval process of medicines for the treatment of restless legs syndrome (RLS): A review of the labels of medicines approved by the FDA and the EMA
2017. EAN Congress – Challenges in translating the Disability Assessment for Dementia (DAD) into 63 languages
2017. ASCP Annual Meeting – Translation of the Zarit Burden Interview 22 Items (ZBI-22) into 95 Languages: challenges and importance of the conceptual definition of the original version
2017. ASCP Annual Meeting – Challenges in Translating the Neuropsychiatric Inventory (NPI) into 74 Languages
2017. ASCP Annual Meeting – Panel Session: Validly and reliably measuring functional performance in dementia patients across countries and languages in clinical trials
2017. ISPOR Annual International Meeting – Importance of clinical outcome assessment (COA) data in the evaluation of medicines for the treatment of Alzheimer’s Disease (AD): A review of the labels of medicines approved by the FDA and the EMA
2017. ISPOR Annual International Meeting – Importance of clinical outcome assessment (COA) data in the evaluation of medicines for the treatment of restless legs syndrome (RLS): A review of the labels of medicines approved by the FDA and the EMA
2017. ISPOR Annual International Meeting – Challenges in translating the Neuropsychiatric Inventory (NPI) into 74 languages
2017. ISPOR Annual International Meeting – Translation of the Zarit Burden Interview 22 items (ZBI-22) into 95 languages: challenges and importance of the conceptual definition of the original version
2017. Journée de neurologie de Langue Française (JNLF) – Facteurs associés à l’acceptance d’un traitement par interferon beta-1a intramusculaire chez des patients souffrant de sclérose en plaques: Résultats de l’étude ADOPTE
2016. ISPOR European Congress – The Cost of Multiple Sclerosis in 16 European Countries: Functional Status, Symptoms and Mental Factors Drive Costs
2016. ISPOR European Congress – Cross-Cultural Adaptation of the Zarit Caregiver Interview for Alzheimer’s Disease (ZCI-AD) and the Caregiver Global Impression Scales in 13 Languages
2016. ISPOR European Congress – Translation of the DN4 (Douleur Neuropathique en 4 Questions) into 85 languages: Challenges and Importance of the Conceptual Definition of the Original Version
2016. ISPOR European Congress – Comparing Different Data on Disease Burden in Multiple Sclerosis
2016. ISOQOL Annual Conference – An Evaluation of the Zarit Caregiver Interview for Alzheimer’s Disease (ZCI-AD)
2016. ISOQOL Annual Conference – Development of the Bayley Scales Third Edition into Nine Languages: The Example of the Expressive Communication Subtest of the Language Scale
2016. ISCTM Autumn Conference – Translation of the National Institutes of Health Stroke Scale (NIHSS) List of Words: Methodology and Challenges
2016. ISCTM Autumn Conference – Clinical Outcome Assessments Used/Recommended by the EMA and FDA for the Evaluation of Products to Treat Autism Spectrum Disorder
2016. ECTRIMS – Factors Associated with Acceptance to Intramuscular Interferon b-1a in Patients with Multiple Sclerosis: Results from the ADOPTE study
2016. European Sleep Research Society Meeting – The Paediatric Narcolepsy Screening Questionnaire: Data from the evaluation of a new tool to help paediatricians diagnose narcolepsy
2016. AAIC – Psychometric Validation of a Novel Scoring Algorithm for the Zarit Caregiver Interview for Alzheimer’s Disease (ZCI-AD)
2016. ASCP Annual Meeting – The Role of Clinical Outcome Assessment (COA) Data in the Drug Approval Process of Products for the Treatment of Autism Spectrum Disorder in the USA and Europe: A Review of Guidance Documents and Authorizations of Medicinal Products
2016. ISPOR Annual International Meeting – Challenges in Translating the Epworth Sleepiness Scale (ESS) into 66 Languages
2016. AAN Annual Meeting – Sick Leave and Disability Pension in Patients with Multiple Sclerosis: A Longitudinal, Observational Study
2016. AAN Annual Meeting – Is Health-Related Quality of Life an Important Evaluation Criterion in Drug Development of Multiple Sclerosis (MS) Products? A Review of Labels of MS Products Approved the FDA and the EMA
2016. AAN Annual Meeting – Concepts Important for Multiple Sclerosis Patient Caregivers: Systematic Literature Review of Qualitative Studies
2015. ISPOR European Congress – Challenges in Translating the Multiple Sclerosis International Quality of Life (MusiQoL) Questionnaire in 57 Languages
2015. ISOQOL Annual Conference – Developing the Guy’s Neurological Disability Scale (GNDS) in 28 Languages
2015. Associated Professional Sleep Societies (SLEEP) Annual Meeting – Developing outcome measures for assessing narcolepsy with cataplexy in children and adolescents
2015. ISPOR Annual International Meeting – Does Health-Related Quality of Life Evaluation in Multiple Sclerosis (MS) Matter? A Review of Labels of MS Products Approved by the FDA and EMA
2015. ISPOR Annual International Meeting – Systematic Literature Review of Treatments of Chronic Cluster Headache
2014. ACTRIMS-ECTRIMS Joint Meeting – Psychometric properties of the Multiple Sclerosis Knowledge Questionnaire
2014. ISPOR Annual International Meeting – The Challenge of Translating the Story Memory Subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) into 24 Languages
2013. ISPOR Annual International Meeting – Cross-Cultural Adaptation of a Research Version of the Rey Auditory Verbal Learning Test (RAVLT) into Japanese
2012. ISPOR European Congress – The Challenge of Translating the Picture Naming Subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
2012. ISOQOL Annual Conference – Review of Methods Used to Translate Neurocognitive Assessments
2012. ISOQOL Annual Conference – The Challenge of Translating the Picture Naming Subtest of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
2012. ISPOR Annual International Meeting – What is the Influence on Clinical Research of the EMA Guideline on Medicinal Products for the Treatment of Alzheimer’s Diseases?
2012. ISPOR Annual International Meeting – Dopamine Agonists and Dyskinesia in Advanced Parkinson’s Disease: A Network Meta-Analysis of Rotogotine, Pramipexole and Ropinirole as Adjunct Therapy to Levodopa
2012. ISPOR Annual International Meeting – Cross-Cultural Adaptation of a Research Version of the Rey Auditory Verbal Learning Test (RAVLT) into (US) Spanish
2011. ISOQOL Annual Conference – Translation of the National Institutes of Health Stroke Scale (NIHSS) List of Sentences: A Challenging Task
2011. ISOQOL Annual Conference – Life Expectancy of a Translation: The Example of the French Version of the Clinical Dementia Rating (CDR) Scale
2011. ISOQOL Annual Conference – Translation of the National Institutes of Health Stroke Scale (NIHSS) List of Words: a Challenging Task
2011. ISPOR Annual International Meeting – Translatability of the Post-Migraine Questionnaire
2011. ISPOR Annual International Meeting – Content Validity of the Multiple Sclerosis International QOL (MUSIQOL) Questionnaire in Iran, Egypt, Morocco, Saudi Arabia and Tunisia
2010. ISPOR European Congress – Difficulties in Identifying the Original Source Questionnaire for Use in Translations: The ADAS-COG Case Study
2010. ISOQOL Annual Conference – Content Validity of Utility Assessments in Type 2 Diabetes and Alzheimer’s Disease.
2010. ISOQOL Annual Conference- The Importance of Guidelines for ClinROs: The ADAS-Cog, a Case Study
2010. ISPOR Annual International Meeting – Management of Acute Ischemic Stroke in the USA
2010. ISPOR Annual International Meeting – Evaluating the Impact of Restless Legs Syndrome (RLS) on Next Day Functioning
2010. ISPOR Annual International Meeting – The Importance of Guidelines for ClinROs: The ADAS-COG, A Case Study
2009. ISPOR European Congress – Linguistic Validation of the Multiple Sclerosis Impact Scale (MSIS-29) for Use in 29 Languages
2009. ISPOR Annual International Meeting – Linguistic Validation of the Attention and Performance Self-Assessment Scale, APSA, for Use in International Studies
2008. ISPOR European Congress – Eliciting Utility Scores for Health States Associated with Lennox-Gastaut Syndrome
2008. ISPOR European Congress – Rufinamide in the Adjunctive Treatment of Lennox-Gastaut Syndrome (LGS): A Cost Effectiveness Analysis.
2006. ISPOR European Congress – A Literature Review of Patient-Reported Outcomes (PROS), Neuropsychological and Cognitive Instruments in Parkinson’s Disease
2005. ISPOR European Congress – Use of the Self-Administered Neuropathy Total Symptom Score – 6 (NTSS-6 SA) in an International Study
1999. ISPOR Annual International Meeting – Linguistic Validation of the Patient Perception of Migraine Questionnaire (PPMQ) in 16 Languages